Victoria Evelyn, PA
Medical · Boulder, CONPI 1114332020
Payments from drug & device makers
Across 182 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$984
- Takeda Pharmaceuticals U.S.A., Inc.$417
- QOL Medical, LLC$407
- Gilead$404
- Ardelyx, Inc.$223
- Johnson & Johnson$176
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,77299%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $984 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $417 |
| QOL Medical, LLC | 23 | $407 |
| Gilead | 19 | $404 |
| Ardelyx, Inc. | 7 | $223 |
| Johnson & Johnson | 7 | $176 |
| Celltrion USA Inc. | 5 | $164 |
| Regeneron Healthcare Solutions, Inc. | 6 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $156 |
| Sanofi | 6 | $131 |
| Lilly USA, LLC | 5 | $105 |
| Aimmune Therapeutics, Inc. | 6 | $105 |
| Pfizer | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Boston Scientific | 1 | $49 |
| Intercept Pharmaceuticals, Inc. | 2 | $38 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Novo Nordisk | 1 | $15 |
How this compares
$3,797 in reported general payments places this provider in the 85th percentile of 766 medical providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 57 | $777 |
| Pantoprazole Sodium | 56 | $508 |
| Famotidine | 40 | $384 |
Paid to pharmacies, not to this prescriber.
Other medical in Boulder
- Christen KutzColorado Springs$2.4M
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
- Lindsey TunstallAurora$87K
- Jennifer NafzigerHighlands Ranch$80K
- Daniel TaylorDenver$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.